Finland· FI-REL-REL56510
JEMPERLI
A dostarlimab product containing dostarlimab, registered in Finland by GlaxoSmithKline Trading Services Limited. The same ATC class is registered in 12 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Dostarlimab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FF07 (dostarlimab), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 8 of them publish a price we can compare per daily dose
Dostarlimab · ATC L01FF07
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Dostarlimab
- Manufacturer
- GlaxoSmithKline Trading Services Limited
- Country
- Finland (FI)
- ATC code
- L01FF07
- ATC class
- Dostarlimab
- Defined daily dose
- 24 mg, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 1
1 priced- fi_myyntilupa45287110 mlEUR 8275.42
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Dostarlimab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaJEMPERLIGlaxoSmithKline Trading Services Limited, Dublin
- BelgiumJemperli 500 mgGlaxoSmithKline Trading Services
- IcelandJemperliGlaxoSmithKline Trading Services Limited
- NorwayJemperliGlaxoSmithKline Trading Services Limited
- SwedenJemperli 500 mg Koncentrat till infusionsvätska, lösningGlaxoSmithKline Trading Services Ltd
- IrelandJEMPERLI 500 mg concentrate for solution for infusionGlaxoSmithKline Trading Services Limited
- SpainJEMPERLI 500 mg CONCENTRADO PARA SOLUCION PARA PERFUSIONGlaxosmithkline Trading Services Limited
- SwitzerlandJemperli
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Jemperli
- Liechtenstein · Jemperli
- Norway · Jemperli
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c259fc18-52b6-47ed-b0e6-0037cc1160b4 GET /v1/drugs/c259fc18-52b6-47ed-b0e6-0037cc1160b4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "infuusiokonsentraatti, liuosta varten",
"route": "Laskimoon",
"ddd_unit": null,
"strength": "500 mg",
"atc_label": "dostarlimabi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/21/1538/001",
"fimea_rel_id": "REL56510",
"authorised_at": "2021-04-21"
}See everything about dostarlimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.